Geron
GERN
1.20
-0.01
-0.83%
Geron
US · GERN
#3440 by market cap
1.20
-0.01
-0.83%
Live - 5344 symbols - heartbeat 292s ago
· 2026-10-08 08:45
Pre-market
1.19
-0.77%
After-hours
1.20
0.00%
Overnight
1.21
+0.83%
- Market cap
- 770.97M
- P/E (TTM)i
- -10.91
- P/Bi
- 3.53
- EPSi
- -0.13
- Div yieldi
- 0.00%
- 52W posi
- 16%
Reader sentiment
Are you bullish or bearish on GERN?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
- Gross margin
- 97.42%
- Operating margin
- -28.04%
- Net margin
- -45.41%
Key ratios & quality
- Enterprise valuei
- 533.60M
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.07M | 460.00K | 253.00K | 1.39M | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | 596.00K | 237.00K | 75.74M | 179.14M |
| Selling & admin expenses | 18.71M | 20.89M | 25.68M | 29.67M | 43.63M | 69.14M | 145.73M | 159.26M |
| Research & development | 13.43M | 52.07M | 51.49M | 85.73M | 95.52M | 125.05M | 103.74M | 71.43M |
| Operating profit | -31.07M | -72.51M | -76.91M | -114.00M | -138.55M | -193.94M | -173.73M | -51.55M |
| Pretax profit | -27.02M | -68.55M | -75.62M | -116.11M | -141.90M | -184.13M | -174.57M | -83.50M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -27.02M | -68.55M | -75.62M | -116.11M | -141.90M | -184.13M | -174.57M | -83.50M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.15 | -0.36 | -0.28 | -0.35 | -0.37 | -0.32 | -0.27 | -0.13 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 39.60M | 49.04M | 47.23M | -- | 51.84M | 57.48M |
| Gross profit | 38.40M | 47.85M | 46.18M | 46.71M | 50.15M | 48.24M |
| Selling & admin expenses | 40.02M | 38.56M | 39.00M | 41.67M | 35.43M | 38.86M |
| Research & development | 15.08M | 21.74M | 21.07M | 13.55M | 14.96M | 22.03M |
| Operating profit | -16.70M | -12.45M | -13.89M | -8.51M | -236.00K | -12.65M |
| Pretax profit | -19.84M | -16.38M | -18.43M | -28.86M | -3.64M | -16.68M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -19.84M | -16.38M | -18.43M | -28.86M | -3.64M | -16.68M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.03 | -0.02 | -0.03 | -0.05 | -0.01 | -0.02 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 166.06M | 141.61M | 199.86M | 187.21M | 180.25M | 341.35M | 490.99M | 520.27M |
| Cash & ST investments | 163.29M | 139.33M | 196.28M | 183.72M | 172.75M | 333.70M | 406.57M | 357.92M |
| Inventory | -- | -- | -- | -- | -- | 0 | 38.71M | 116.64M |
| Total assets | 185.28M | 165.52M | 270.73M | 226.03M | 190.58M | 394.08M | 593.78M | 570.54M |
| Total current liabilities | 7.55M | 28.16M | 30.94M | 45.52M | 76.69M | 108.07M | 88.30M | 111.54M |
| Short-term debt | -- | 354.00K | 878.00K | 901.00K | 21.87M | 47.84M | 974.00K | 1.00M |
| Long-term debt | -- | -- | 24.04M | 49.83M | 30.21M | 35.05M | 118.48M | 119.55M |
| Total liabilities | 7,551,000.00 | 30,362,000.00 | 59,781,000.00 | 99,618,000.00 | 110,577,000.00 | 146,127,000.00 | 313,461,000.00 | 344,668,000.00 |
| Total equity | 177.73M | 135.16M | 210.95M | 126.42M | 80.00M | 247.95M | 280.32M | 225.87M |
| Retained earnings | -1.01B | -1.08B | -1.16B | -1.27B | -1.41B | -1.60B | -1.77B | -1.86B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 495.77M | 505.60M | 522.34M | 520.27M | 498.53M | 486.34M |
| Cash & ST investments | 396.88M | 387.98M | 380.53M | 357.92M | 312.40M | 300.85M |
| Inventory | 56.22M | 69.13M | 95.42M | 116.64M | 133.29M | 123.60M |
| Total assets | 562.45M | 555.20M | 567.38M | 570.54M | 534.12M | 519.01M |
| Total current liabilities | 63.03M | 64.28M | 87.71M | 111.54M | 73.57M | 70.33M |
| Short-term debt | 981.00K | 987.00K | 994.00K | 1.00M | 1.01M | 1.01M |
| Long-term debt | 118.73M | 118.99M | 119.26M | 119.55M | 119.83M | 120.13M |
| Total liabilities | 294,212,000.00 | 295,667,000.00 | 318,675,000.00 | 344,668,000.00 | 305,012,000.00 | 300,395,000.00 |
| Total equity | 268.24M | 259.53M | 248.71M | 225.87M | 229.11M | 218.61M |
| Retained earnings | -1.79B | -1.81B | -1.83B | -1.86B | -1.86B | -1.88B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -21.01M | -43.83M | -66.65M | -95.56M | -127.38M | -167.74M | -218.62M | -111.04M |
| Depreciation & amortization | 59.00K | 776.00K | 935.00K | 783.00K | 868.00K | 1.03M | 1.22M | 1.20M |
| Free cash flow | -21.03M | -44.24M | -67.05M | -95.76M | -127.81M | -168.57M | -219.30M | -111.09M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 86.02M | 19.30M | 144.26M | 20.39M | 69.92M | 213.34M | 140.73M | 0 |
| Ending cash balance | 10.84M | 13.91M | 10.29M | 35.24M | 57.21M | 71.14M | 80.88M | 79.44M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -47.98M | -27.42M | -13.58M | -22.07M | -62.91M | -15.83M |
| Depreciation & amortization | 308.00K | 309.00K | 312.00K | 275.00K | 326.00K | 332.00K |
| Free cash flow | -47.98M | -27.55M | -13.49M | -22.07M | -63.16M | -16.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 85.61M | 79.60M | 79.99M | 79.44M | 70.78M | 64.53M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -19.19 | -43.82 | -43.70 | -68.84 | -137.49 | -112.29 | -66.09 | -32.99 |
| ROA %i | -18.28 | -39.08 | -34.67 | -46.75 | -68.12 | -62.99 | -35.34 | -14.34 |
| ROIC %i | -21.53 | -45.77 | -40.53 | -53.50 | -86.74 | -82.61 | -47.75 | -18.40 |
| 5-year avg ROE %i | -20.73 | -22.00 | -30.74 | -40.05 | -62.61 | -81.23 | -85.68 | -83.54 |
| EBIT margin %i | -2,914.92 | -15,761.96 | -29,587.75 | -8,066.91 | -22,654.19 | -74,183.54 | -202.70 | -27.65 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 21.99 | 5.03 | 6.46 | 4.11 | 2.35 | 3.16 | 5.56 | 4.66 |
| Quick ratioi | 21.78 | 4.98 | 6.37 | 4.07 | 2.29 | 3.10 | 5.04 | 3.56 |
| Debt / assetsi | 0.00 | 1.54 | 10.98 | 24.33 | 29.26 | 21.80 | 20.50 | 21.38 |
| LT debt / equityi | -- | 1.63 | 13.67 | 42.79 | 42.35 | 15.35 | 43.07 | 53.57 |
| Interest coveragei | -- | -- | -98.50 | -30.05 | -19.62 | -21.15 | -8.43 | -1.56 |
| Revenue CAGR (3Y) %i | -69.17 | -57.89 | -38.07 | 9.33 | 9.02 | -2.15 | 280.92 | 575.72 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -45.35 | -31.09 | -29.57 | -32.99 | -27.07 | -28.28 |
| ROA %i | -26.62 | -17.52 | -15.80 | -14.34 | -12.28 | -12.59 |
| ROIC %i | -33.18 | -20.48 | -17.37 | -18.40 | -14.06 | -14.42 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -99.53 | -36.21 | -25.04 | -27.65 | -18.21 | -18.27 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.87 | 7.87 | 5.96 | 4.66 | 6.78 | 6.92 |
| Quick ratioi | 6.84 | 6.65 | 4.77 | 3.56 | 4.85 | 5.04 |
| Debt / assetsi | 21.65 | 21.95 | 21.49 | 21.38 | 22.85 | 23.53 |
| LT debt / equityi | 45.03 | 46.57 | 48.62 | 53.57 | 52.84 | 55.41 |
| Interest coveragei | -4.97 | -2.09 | -1.35 | -1.56 | -1.13 | -1.24 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development of therapeutic products for oncology100.00%
Region
United States100.00%
Quote time 2026-10-08 08:45:12 · For reference only, not investment advice and not tailored to your situation.